The Impact of Disease Activity on Hematological Parameters among Rheumatoid Arthritis Patients: A Cross-Sectional Analysis

Authors

  • Rana Mohsen University of Anbar‎
  • Hajar khaled Masser University of Anbar
  • Mostafa Nuhad Al daraji University of Anbar

DOI:

https://doi.org/10.32792/utq/utjsci/v12i2.1434

Abstract

ABSTRACT:Background: “Rheumatoid arthritis (RA) is a systemic autoimmune disorder primarily marked by persistent inflammation of the synovial joints, often accompanied by extra-articular involvement that can affect multiple organ systems. Although extensive research has investigated inflammatory and hematological parameters among Iraqi RA patients, there is still a significant gap in region-specific data, particularly concerning patients from Anbar Governorate.Objectives: “This investigation sought to assess and compare the concentrations of key inflammatory and immunological markers—including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide (Anti-CCP) antibodies, white blood cell (WBC) count, as well as interleukins IL-17 and IL-21—between patients diagnosed with rheumatoid arthritis and healthy individuals residing in Anbar, Iraq. Methods: A case-control study was conducted involving 50 RA patients and 40 healthy controls. Hematological and immunological markers (ESR, CRP, RF, Anti-CCP, WBC) were measured using routine laboratory techniques, while IL-17 and IL-21 were quantified using ELISA. Statistical significance was set at p < 0.05.Results:RA patients demonstrated significantly elevated ESR and CRP levels compared to controls (P < 0.001). RF and Anti-CCP were exclusively positive in patients, with none of the controls testing positive (P < 0.001), indicating strong diagnostic value. WBC, IL-17, and IL-21 levels showed no statistically significant differences, although patients exhibited a mild non-significant increase Conclusion:ESR, CRP, RF, and Anti-CCP proved to be highly informative markers for differentiating RA patients from healthy individuals. Conversely, WBC, IL-17, and IL-21 demonstrated limited value when used alone.

References

‎[1] S. Berardi, A. Corrado, N. Maruotti, D. Cici, and F. ‎Cantatore, “Osteoblast role in the pathogenesis of ‎rheumatoid arthritis,” Molecular Biology Reports, ‎‎2021, doi: 10.1007/s11033-021-06288-y.‎

‎[2] M. Anton, A. Cardoneanu, A. Burlui, I. Mihai, P. ‎Richter, I. Bratoiu, L. Macovei, and E. Rezu, “The ‎lung in rheumatoid arthritis—friend or enemy,” ‎International Journal of Molecular Sciences, vol. ‎‎25, no. 12, Art no. 6460, 2024, doi: ‎‎10.3390/ijms25126460.‎

‎[3] H. Almoallim, J. A. Saleh, H. Badsha, H. Ahmed, S. ‎Habjoka, J. Menassa, and A. El-Garf, “A review of ‎the prevalence and unmet needs in the management ‎of rheumatoid arthritis in africa and the middle east,” ‎Rheumatology and Therapy, 2020, doi: ‎‎10.1007/s40744-020-00252.‎

‎[4] M. Zen, L. Salmaso, C. B. Amidei, A. Giollo, U. ‎Fedeli, S. Bellio, F. Arru, I. Gennaio, M. Saia, and A. ‎Doria, “Ab1628the incidence and prevalence of ‎rheumatoid arthritis in italy in the last decade,” ‎Annals of the Rheumatic Diseases, 2023, doi: ‎‎10.1136/annrheumdis-2023-eular.1432.‎

‎[5] L. Silva-Fernández, C. Macía-Villa, D. Seoane-Mato, ‎R. Cortés-Verdú, A. Romero-Pérez, V. Quevedo-Vila, ‎D. Fábregas-Canales, F. Antón-Pagés, G. Añez, A. ‎Brandy, C. Martínez-Dubois, P. Sánchez-Piedra, C. ‎Sánchez-Piedra, F. Díaz-González, and S. Bustabad-‎Reyes, “The prevalence of rheumatoid arthritis in ‎spain,” Scientific Reports, 2020, doi: ‎‎10.1038/s41598-020-76511-6.‎

‎[6] M. Jahid, K. U. Khan, Rehan-Ul-Haq, and R. S. ‎Ahmed, “Overview of rheumatoid arthritis and ‎scientific understanding of the disease,” ‎Mediterranean Journal of Rheumatology, 2023, doi: ‎‎10.31138/mjr.20230801.oo.‎

‎[7] N. Lapkina, A. Baranov, N. Levshin, N. Abatova, A. ‎Avdeeva, E. Leontieva, A. Artyuhov, and E. ‎Nasonov, “Pos0668the efficacy of tofacitinib on ‎clinical dynamic and concentration of cytokines in ‎patients with rheumatoid arthritis,” Annals of the ‎Rheumatic Diseases, 2022, doi: ‎‎10.1136/annrheumdis-2022-eular.354.‎

‎[8] N. Kondo, T. Kuroda, and D. Kobayashi, “Cytokine ‎networks in the pathogenesis of rheumatoid ‎arthritis,” International Journal of Molecular ‎Sciences, vol. 22, no. 20, Art no. 10922, 2021, doi: ‎‎10.3390/ijms222010922.‎

‎[9] H. Yap, S. Tee, M. M. Wong, S. Chow, S. Peh, and S. ‎Teow, “Pathogenic role of immune cells in ‎rheumatoid arthritis: implications in clinical ‎treatment and,” Cells, vol. 7, no. 10, Art no. 161, ‎‎2018, doi: 10.3390/cells7100161.‎

‎[10] M. Taha, O. Shaker, E. Abdelsalam, and N. Taha, ‎‎“Serum a proliferation-inducing ligand and ‎microrna-223 are associated with rheumatoid ‎arthritis: diagnostic and prognostic implications,” ‎Molecular Medicine, 2020, doi: 10.1186/s10020-‎‎020-00199-7.‎

‎[11] Q. Guo, Y. Wang, D. Xu, J. Nossent, N. Pavlos, and J. ‎Xu, “Rheumatoid arthritis: pathological mechanisms ‎and modern pharmacologic therapies,” Bone ‎Research, 2018, doi: 10.1038/s41413-018-0016-9.‎

‎[12] Y. Ma, H. Chen, W. Lv, S. Wei, Y. Zou, R. Li, J. ‎Wang, W. She, L. Yuan, J. Tao, X. Guo, S. Bi, H. Tian, ‎Y. Ma, H. Sun, C. Sun, J. Xu, Y. Dong, J. Kang, and Y. ‎Jiang, “Global, regional and national burden of ‎rheumatoid arthritis from 1990 to 2021, with ‎projections of incidence to 2050: a systematic and ‎comprehensive analysis of the global burden of ‎disease study 2021,” Biomarker Research, 2025, doi: ‎‎10.1186/s40364-025-00760-8.‎

‎[13] L. M. Alm, D. L. Fountain, K. K. Cadwell, A. M. ‎Madrigal, G. Gallo, and M. Poorafshar, “The ‎performance of anti-cyclic citrullinated peptide ‎assays in diagnosing rheumatoid arthritis: a ‎systematic review and meta-analysis,” Clin Exp ‎Rheumatol, vol. 36, pp. 144-152, 2018.‎

‎[14] M. A. M. van Delft and T. W. J. Huizinga, “An ‎overview of autoantibodies in rheumatoid arthritis,” ‎J Autoimmun, vol. 110, Art no. 102392, 2020, doi: ‎‎10.1016/j.jaut.2019.102392.‎

‎[15] T. Webb, G. Lakos, A. Swart, et al., “Clinical ‎evaluation of a novel chemiluminescent ‎immunoassay for the detection of anti-citrullinated ‎peptide antibodies,” Clin Chim Acta, vol. 437, pp. ‎‎161-167, 2014.‎

‎[16] E. D. Gahli and H. Q. Mohammed, “Evaluation of ‎demographic, serological and hematological data ‎features in patients diagnosed with rheumatoid ‎arthritis in Wasit Province,” Journal of Basrah ‎Researches (Sciences), vol. 50, no. 2, pp. 204-216, ‎‎2024, doi: 10.56714/bjrs.50.2.17.‎

‎[17] R. M. Khadim and F. S. Al-Fartusie, “Evaluation of ‎liver function and lipid profiles in Iraqi patients with ‎rheumatoid arthritis,” Journal of Physics: ‎Conference Series, vol. 1853, no. 1, Art no. 012040, ‎‎2021, doi: 10.1088/1742-6596/1853/1/012040.‎

‎[18] S. A. Khalaf, E. A. Muhsin, H. K. Ali, and W. Y. ‎Hasan, “Evaluation of the changes in some ‎hematological and immunological parameters in ‎patients with rheumatoid arthritis,” Osol Journal of ‎Medical Sciences, vol. 2024, no. 02, pp. 41-46, 2024, ‎doi: 10.69946/ojms/2024.02.02.05.‎

‎[19] N. A. Salman, “Assessment the role of erythrocyte ‎sedimentation rate and C-reactive protein tests for ‎prediction of rheumatoid arthritis activity in Misan ‎Province,” Al-Manara College for Medical Sciences, ‎‎2024. [Online]. Available: ‎naderabed@uomanara.edu.iq.‎

‎[20] A. K. Zgair and R. H. Ahmad, “Immunological and ‎biological manifestation of rheumatoid arthritis ‎patient in Iraq,” Indian Journal of Forensic ‎Medicine & Toxicology, vol. 15, no. 4, p. 1344, 2021.‎

‎[21] Z. J. Diwan and W. A. Al-Marsomy, “Evaluation of ‎several hematologic and serological parameters in ‎rheumatoid arthritis patients,” Journal of the Faculty ‎of Science for Women, University of Baghdad, vol. ‎‎37, no. 2, 2024, doi: 10.30526/37.2.3451.‎

‎[22] S. A. Salman and R. M. Kh. Al-Jumaily, ‎‎“Immunological role of IL-3, IL-5 and some ‎inflammation markers in a sample of Iraqi patients ‎with rheumatoid arthritis,” Journal of Education for ‎Pure Science, vol. 37, no. 4, Art no. 3493, 2024, doi: ‎‎10.30526/37.4.3493.‎

‎[23] M. H. Sulaiman, R. M. Rashied, and L. A. Mahmood, ‎‎“Evaluation of the lipid profile and its correlation to ‎inflammatory markers in a sample of rheumatoid ‎arthritis patients in Iraq,” Journal of University of ‎Anbar for Pure Science, vol. 17, no. 1, pp. 33-41, ‎‎2023.‎

‎[24] I. A. Chiad, H. S. Yossef, M. A. Al-Saidi, and M. A. ‎Abbas, “Evaluation of some immunological markers ‎in the rheumatoid arthritis patients,” Iraqi Journal of ‎Science, vol. 56, no. 3C, pp. 2488-2493, 2015. ‎‎[Online]. Available: ‎https://ijs.uobaghdad.edu.iq/index.php/eijs/article/view/1485.‎

‎[25] M. A. Al-Karkhi, A. R. Al-Derzi, S. M. H. ‎Mohammed Zeiny, N. A. Jassim, B. M. Mahdi, and ‎M. M. Al-Ani, “Correlation between anti-infliximab ‎and anti-CCP antibodies development in patients ‎with rheumatoid arthritis treated with infliximab in ‎Baghdad Teaching Hospital,” IOSR Journal of Dental ‎and Medical Sciences, vol. 14, no. 11, pp. 95-100, ‎‎2015. [Online]. Available: ‎http://www.iosrjournals.org/iosr-jdms/papers/Vol14-‎issue11/Version-4/P01411495100.pdf.‎

‎[26] D. A. K. Ali, M. M. Al-Ani, N. A. L. Al-Ani, and A. ‎Al-Rubaee, “Assessment of the correlation between ‎disease activity and serum biomarker Anti-MCV and ‎IL6 in Iraqi patients with rheumatoid arthritis,” ‎Journal of the Faculty of Medicine Baghdad, vol. 66, ‎no. 1, Art no. e2359, 2024, doi: ‎‎10.32007/jfacmedbaghdad.6632359.‎

‎[27] S. A. Shahrazad, W. Y. Hasan, and H. M. Kareem, ‎‎“Serological and inflammatory markers in female ‎patients with rheumatoid arthritis in Baghdad,” ‎Baghdad Science Journal, vol. 20, no. 3, p. 455461, ‎‎2025. [Online]. Available: ‎https://iasj.rdd.edu.iq/viewarticle.html?id=14ae4c3d‎94511124b24816665f83dc89.‎

‎[28] Y. H. Lee and S.-C. Bae, “Associations between ‎circulating IL-17 levels and rheumatoid arthritis and ‎between IL-17 gene polymorphisms and disease ‎susceptibility: A meta-analysis,” Postgraduate ‎Medical Journal, vol. 93, no. 1102, pp. 465-471, ‎‎2017, doi: 10.1136/postgradmedj-2016-134637.‎

‎[29] M. Robert and P. Miossec, “IL-17 in rheumatoid ‎arthritis and precision medicine: From synovitis ‎expression to circulating bioactive levels,” Frontiers ‎in Medicine, vol. 5, Art no. 364, 2019, doi: ‎‎10.3389/fmed.2018.00364.‎

‎[30] P. Bhattacharya, S. F. Alam, A. Singh, and S. Ghosh, ‎‎“Interleukin-17F gene polymorphisms and ‎susceptibility to rheumatoid arthritis: a meta-‎analysis,” Scientific Reports, vol. 13, no. 1, Art no. ‎‎1432, 2023, doi: 10.1038/s41598-023-46888-1. ‎

Downloads

Published

2025-12-28

Issue

Section

Articles

Categories

How to Cite

Mohsen, R., Hajar khaled Masser, & Mostafa Nuhad Al daraji. (2025). The Impact of Disease Activity on Hematological Parameters among Rheumatoid Arthritis Patients: A Cross-Sectional Analysis. University of Thi-Qar Journal of Science, 12(2), 110-116. https://doi.org/10.32792/utq/utjsci/v12i2.1434